GlassScriptPhysician profile
Shereene A Grant
NPI 1033505375
$630.26
in general payments reported to CMS, 2019-2025
24 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.57 · 2020: $44.95 · 2022: $151 · 2023: $107 · 2024: $113 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $59.79 | 2019-2023 | |
| Corium, LLC | $48.86 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $47.54 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $46.51 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sobi, INC | $40.77 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.44 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $37.16 | 2024-2025 | Shingrix, Bexsero, Arexvy |
| Abbvie INC. | $34.89 | 2022-2025 | |
| Axsome Therapeutics, INC. | $31.66 | 2025 | Auvelity |
| Lundbeck LLC | $22.89 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $19.49 | 2023 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $19.36 | 2022 | |
| Organon LLC | $19.07 | 2025 | Nuvaring, Nexplanon |
| Allergan, INC. | $17.68 | 2020 | |
| Exeltis, USA INC. | $17.24 | 2024 | Slynd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.69 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $14.42 | 2023 | |
| Lilly USA, LLC | $14.24 | 2022 | |
| Biogen, INC. | $13.83 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $13.49 | 2022 | |
| Novo Nordisk INC | $13.41 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereene Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.